ARS Pharma Q2 net loss $12.5M; neffy PDUFA Oct 2; cash $218.7M

ARS Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.24 revenue$500,000

Cash, equivalents and short-term investments $218.7M as of June 30, 2024, providing at least three years of operating runway.
Net loss $12.5M vs $17.4M in Q2 2023; R&D $6.9M, G&A $8.9M.
neffy NDA under FDA review; draft physician labeling received; PDUFA target action date October 2, 2024.
EURneffy received CHMP positive opinion; formal EU marketing authorization expected Q3 2024.
Phase 2b outpatient study of neffy for urticaria on track to start dosing in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.